Toll Free: 1-888-928-9744

Liposarcoma - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Liposarcoma - Pipeline Review, H2 2014


Global Markets Direct's, 'Liposarcoma - Pipeline Review, H2 2014', provides an overview of the Liposarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Liposarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Liposarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Liposarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liposarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liposarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liposarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Liposarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Liposarcoma - Overview 7
Pipeline Products for Liposarcoma - Comparative Analysis 8
Liposarcoma - Therapeutics under Development by Companies 9
Liposarcoma - Therapeutics under Investigation by Universities/Institutes 10
Liposarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Liposarcoma - Products under Development by Companies 13
Liposarcoma - Products under Investigation by Universities/Institutes 14
Liposarcoma - Companies Involved in Therapeutics Development 15
AtheroNova Inc. 15
BioSpecifics Technologies Corp. 16
Karyopharm Therapeutics, Inc. 17
Novartis AG 18
Pfizer Inc. 19
Sanofi 20
Liposarcoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AHRO-010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
collagenase clostridium histolyticum - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
everolimus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LEE-011 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
palbociclib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SAR-405838 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
selinexor - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Thiazolidinediones + Retinoid X Receptor Selective Agonists - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Liposarcoma - Recent Pipeline Updates 52
Liposarcoma - Product Development Milestones 76
Featured News & Press Releases 76
Jun 26, 2012: BioSpecifics Initiates XIAFLEX Phase II Trial For Human Lipomas 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78
List of Tables
Number of Products under Development for Liposarcoma, H2 2014 7
Number of Products under Development for Liposarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Liposarcoma - Pipeline by AtheroNova Inc., H2 2014 15
Liposarcoma - Pipeline by BioSpecifics Technologies Corp., H2 2014 16
Liposarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 17
Liposarcoma - Pipeline by Novartis AG, H2 2014 18
Liposarcoma - Pipeline by Pfizer Inc., H2 2014 19
Liposarcoma - Pipeline by Sanofi, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Assessment by Combination Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Liposarcoma Therapeutics - Recent Pipeline Updates, H2 2014 52 

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.